Yinuo Wu

Dr. Yinuo Wu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2016 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
Yinuo WuYinuo Wu
Yinuo Wu
LSLei Sun
Lei Sun
YCYunyun Chen
Yunyun Chen
Qian ZhouQian Zhou
Qian Zhou
JHJia-Wu Huang
Jia-Wu Huang
HLHai-Bin Luo
Hai-Bin Luo

19 March 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YHYi-You Huang
Yi-You Huang
YYYan-Fa Yu
Yan-Fa Yu
CZChen Zhang
Chen Zhang
YCYiping Chen
Yiping Chen
Qian ZhouQian Zhou
Qian Zhou
HLHai-Bin Luo
Hai-Bin Luo

18 January 2017 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
CZChen Zhang
Chen Zhang
LFLing-Jun Feng
Ling-Jun Feng
YHYiyou Huang
Yiyou Huang
DWDeyan Wu
Deyan Wu
ZLZhe Li
Zhe Li
HLHai-Bin Luo
Hai-Bin Luo

23 August 2017 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
YYYan-Fa Yu
Yan-Fa Yu
YHYa-Dan Huang
Ya-Dan Huang
CZChen Zhang
Chen Zhang
XWXu-Nian Wu
Xu-Nian Wu
Qian ZhouQian Zhou
Qian Zhou
HLHai-Bin Luo
Hai-Bin Luo

10 February 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XYXianyuan Yang
Xianyuan Yang
KHKaitao Huang
Kaitao Huang
XWXu-Nian Wu
Xu-Nian Wu
CZChen Zhang
Chen Zhang
YSYixuan Sun
Yixuan Sun
HWHongsheng Wang
Hongsheng Wang

22 December 2017 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
CZChen Zhang
Chen Zhang
Qian ZhouQian Zhou
Qian Zhou
XWXu-Nian Wu
Xu-Nian Wu
YHYa-Dan Huang
Ya-Dan Huang
JZJie Zhou
Jie Zhou
HLHai-Bin Luo
Hai-Bin Luo
Phosphodiesterase-9 (PDE9) is a promising target for treatment of Alzheimer’s disease (AD). To discover multifunctional anti-AD agents with capability of PDE9 inhibition and antioxidant activity, a series of novel pyrazolopyrimidinone derivatives, coupling with the pharmacophore of antioxidants such as ferulic and lipolic acids have been designed with the assistance of molecular docking and dynamics simulations. Twelve out of 14 synthesised compounds inhibited PDE9A with IC50 below 200 nM, and showed good antioxidant capacities in the ORAC assay. Compound 1h, the most promising multifunctional anti-AD agent, had IC50 of 56 nM against PDE9A and good antioxidant ability (ORAC (trolox) = 3.3). The selectivity of 1h over other PDEs was acceptable. In addition, 1h showed no cytotoxicity to human neuroblastoma SH-SY5Y cells. The analysis on structure-activity relationship (SAR) and binding modes of the compounds may provide insight into further modification.